MA35233B1 - Molecules de liaison bispecifiques se liant à dii4 et ang2 - Google Patents

Molecules de liaison bispecifiques se liant à dii4 et ang2

Info

Publication number
MA35233B1
MA35233B1 MA36275A MA36275A MA35233B1 MA 35233 B1 MA35233 B1 MA 35233B1 MA 36275 A MA36275 A MA 36275A MA 36275 A MA36275 A MA 36275A MA 35233 B1 MA35233 B1 MA 35233B1
Authority
MA
Morocco
Prior art keywords
ang2
binding
binding molecules
dii4
bispecific binding
Prior art date
Application number
MA36275A
Other languages
English (en)
Inventor
Andreas Gschwind
Rene Georg Ott
Joachim Boucneau
Marie-Ange Buyse
Erik Depla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35233(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA35233B1 publication Critical patent/MA35233B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des molécules de liaison bispécifiques se liant à la fois à dll4 et ang2, de préférence sous la forme de domaines variables uniques d'immunoglobuline comme vhhs et d'anticorps de domaine, les compositions pharmaceutiques contenant celles-ci et leur utilisation dans le traitement de maladies qui sont associées à des effets médiés par dll4 et/ou ang2 sur l'angiogenèse. De plus, l'invention concerne aussi les acides nucléiques codant les molécules de liaison bispécifiques, les cellules hôtes et les procédés pour la préparation de ceux-ci.
MA36275A 2011-04-01 2013-09-27 Molecules de liaison bispecifiques se liant à dii4 et ang2 MA35233B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160920 2011-04-01
PCT/EP2012/055897 WO2012131076A1 (fr) 2011-04-01 2012-03-30 Molécules de liaison bispécifiques se liant à dll4 et ang2

Publications (1)

Publication Number Publication Date
MA35233B1 true MA35233B1 (fr) 2014-07-03

Family

ID=44314095

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36275A MA35233B1 (fr) 2011-04-01 2013-09-27 Molecules de liaison bispecifiques se liant à dii4 et ang2

Country Status (23)

Country Link
US (1) US20130078247A1 (fr)
EP (1) EP2694545B1 (fr)
JP (1) JP2014511682A (fr)
KR (1) KR20140016345A (fr)
CN (2) CN103596977B (fr)
AP (1) AP2013007086A0 (fr)
AR (1) AR085919A1 (fr)
AU (1) AU2012234218A1 (fr)
BR (1) BR112013025294A2 (fr)
CA (1) CA2827809A1 (fr)
CL (1) CL2013002622A1 (fr)
CO (1) CO6801638A2 (fr)
EA (1) EA201301109A1 (fr)
EC (1) ECSP13012996A (fr)
MA (1) MA35233B1 (fr)
MX (1) MX337115B (fr)
PE (1) PE20141157A1 (fr)
PH (1) PH12013502031A1 (fr)
SG (1) SG193557A1 (fr)
TN (1) TN2013000389A1 (fr)
TW (2) TWI551612B (fr)
UY (1) UY33997A (fr)
WO (1) WO2012131076A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EA031182B1 (ru) * 2012-03-30 2018-11-30 Бёрингер Ингельхайм Интернациональ Гмбх Ang2-связывающие молекулы
KR20150060687A (ko) * 2012-09-28 2015-06-03 베링거 인겔하임 인터내셔날 게엠베하 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF-R 제제를 포함하는 약제학적 조합물
EA201500371A1 (ru) * 2012-09-28 2015-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
CN107540747B (zh) * 2017-08-09 2020-01-24 苏州大学附属儿童医院 抗人dll4单克隆抗体6f12
CN110950967B (zh) * 2019-12-13 2022-05-13 山东民康生物科技有限公司 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
KR20240048555A (ko) * 2021-09-10 2024-04-15 소테르 바이오파마 피티이. 리미티드 항 ang2 항체 및 그 제조방법과 응용
CN116444675B (zh) * 2023-05-11 2023-12-22 亲和(武汉)生命科技有限责任公司 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用
WO2025111816A1 (fr) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Protéines de fusion multispécifiques ciblant des facteurs angiogéniques, inflammatoires et/ou fibrotiques

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP2275557A1 (fr) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Protéines de fusion d'albumine
EP2316951A1 (fr) 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Proteines de fusion d'immunoglobuline de domaine de liaison
WO2003002609A2 (fr) 2001-06-28 2003-01-09 Domantis Limited Ligand
CA2484556A1 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Proteines de fusion d'albumine
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2006519763A (ja) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
KR101025143B1 (ko) 2002-12-31 2011-04-01 넥타르 테라퓨틱스 가수분해상으로 안정한 말레이미드－종결 중합체
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
JP5113523B2 (ja) 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
EP2949668B1 (fr) * 2005-05-18 2019-08-14 Ablynx N.V. Nanobodies tm améliorés contre le facteur alpha de la nécrose des tumeurs
NZ568739A (en) * 2005-12-16 2010-09-30 Regeneron Pharma Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
CA2654000A1 (fr) * 2006-06-06 2008-05-22 Genentech, Inc. Anticorps anti-dll4 et leurs procedes d'utilisation
CN101489576A (zh) * 2006-06-06 2009-07-22 健泰科生物技术公司 用于调节血管发育的组合物和方法
CA2654304A1 (fr) 2006-06-06 2007-12-13 Genentech, Inc. Compositions et procedes destines a moduler le developpement vasculaire
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2069402A2 (fr) * 2006-09-08 2009-06-17 Ablynx N.V. Protéines à demi-vie longue se liant à l'albumine sérique
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
ES2667863T3 (es) * 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
WO2009109635A2 (fr) 2008-03-05 2009-09-11 Ablynx Nv Nouveaux complexes dimères de fixation à des antigènes, procédés de fabrication et utilisations associés
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2009294415B2 (en) * 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2

Also Published As

Publication number Publication date
TN2013000389A1 (en) 2015-01-20
CN106046167A (zh) 2016-10-26
UY33997A (es) 2012-09-28
TW201302797A (zh) 2013-01-16
BR112013025294A2 (pt) 2017-06-13
AU2012234218A1 (en) 2013-09-05
AP2013007086A0 (en) 2013-08-31
NZ614243A (en) 2015-04-24
TWI551612B (zh) 2016-10-01
TWI535735B (zh) 2016-06-01
CL2013002622A1 (es) 2014-02-14
AR085919A1 (es) 2013-11-06
CN103596977A (zh) 2014-02-19
EA201301109A1 (ru) 2014-08-29
PH12013502031A1 (en) 2013-12-16
ECSP13012996A (es) 2013-12-31
CA2827809A1 (fr) 2012-10-04
EP2694545B1 (fr) 2016-08-24
MX2013011032A (es) 2013-12-06
CN103596977B (zh) 2016-07-06
MX337115B (es) 2016-02-12
PE20141157A1 (es) 2014-09-24
US20130078247A1 (en) 2013-03-28
SG193557A1 (en) 2013-11-29
TW201302789A (zh) 2013-01-16
KR20140016345A (ko) 2014-02-07
JP2014511682A (ja) 2014-05-19
WO2012131076A1 (fr) 2012-10-04
CO6801638A2 (es) 2013-11-29
EP2694545A1 (fr) 2014-02-12

Similar Documents

Publication Publication Date Title
MA34979B1 (fr) Molecules de liaisonbispecifiques se liant a vegf et ang2
MA35233B1 (fr) Molecules de liaison bispecifiques se liant à dii4 et ang2
MA33609B1 (fr) Molecules de liaison a dll4
MA33607B1 (fr) Molécules de liaison bispécifiques pour une thérapie anti-angiogénique
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MA44547B1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
EA201590613A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения
MA56289A (fr) Mutéines d'interleukine-21 et méthodes de traitement
MA33815B1 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
MA37794A1 (fr) Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
EA201492253A1 (ru) Конструкторы, связывающиеся с ron, и способы их использования
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA46647A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
IN2014MN01781A (fr)
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
BR112015017619A2 (pt) formulação líquida, uso de uma formulação, e, kit
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
EA200970250A1 (ru) Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
EA201492149A1 (ru) St2-антигенсвязывающие белки
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
MA39342B2 (fr) Anticorps il -21
MY200710A (en) Novel fusion protein specific for cd137 and pd-l1
EA202090372A1 (ru) Универсальные соединения авт и их применение